The "Traditional Chinese medicine regulating liver regeneration" treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data

被引:3
|
作者
Dai, Ling [1 ,2 ,3 ,4 ]
Gao, Xiang [1 ,2 ,3 ,4 ]
Ye, Zhihua [1 ,2 ,3 ,4 ]
Li, Hanmin [1 ,2 ,3 ,4 ]
Yao, Xin [1 ,2 ,3 ,4 ]
Lu, Dingbo [1 ,2 ,3 ,4 ]
Wu, Na [1 ,2 ,3 ,4 ]
机构
[1] Hubei Prov Hosp Tradit Chinese Med, Inst Liver Dis, Wuhan 430061, Peoples R China
[2] Hubei Prov Acad Tradit Chinese Med, Inst Basic Theory Chinese Med, Wuhan 430074, Peoples R China
[3] Hubei Prov Key Lab, Theory & Applicat Res Liver & Kidney Tradit Chine, Wuhan 430074, Peoples R China
[4] State Adm Tradit Chinese Med, Key Lab Treating Chron Liver Dis Liver & Kidney, Wuhan 430061, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatitis B virus-related liver failure; traditional Chinese medicine; liver regeneration; liver regeneration microenvironment; cytokines; THERAPEUTIC-EFFICACY; LIPID-ACCUMULATION; STEM-CELLS; EXPRESSION; APOPTOSIS;
D O I
10.1007/s11684-020-0790-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
On the basis of real-world clinical data, the study aimed to explore the effect and mechanisms of the treatment plan of "traditional Chinese medicine (TCM) regulating liver regeneration." A total of 457 patients with HBV-related liver failure were retrospectively collected. The patients were divided into three groups: the modern medicine control group (MMC group), patients treated with routine medical treatment; the control group combining traditional Chinese and Western medicine (CTW), patients treated with routine medical treatment plus the common TCM formula; and the treatment group of "TCM regulating liver regeneration" (RLR), patients treated with both routine medical treatment and the special TCM formula of RLR. After 8 weeks of treatment, the mortality of patients in the RLR group (12.31%) was significantly lower than those in the MMC (50%) and CTW (29.11%) groups. Total bilirubin level significantly decreased and albumin increased in the RLR group when compared with the MMC and CTW groups (P < 0.05). In addition, there were significant differences in the expression of several cytokines related to liver regeneration in the RLR group compared with the MMC group. RLR treatment can decrease jaundice, improve liver function, and significantly reduce the mortality in patients with HBV-related liver failure. The mechanism may be related to the role of RLR treatment in influencing cytokines related to liver regeneration.
引用
收藏
页码:495 / 505
页数:11
相关论文
共 41 条
  • [31] A machine learning model for predicting abnormal liver function induced by a Chinese herbal medicine preparation (Zhengqing Fengtongning) in patients with rheumatoid arthritis based on real-world study
    Yu, Ze
    Kou, Fang
    Gao, Ya
    Gao, Fei
    Lyu, Chun-ming
    Wei, Hai
    JOURNAL OF INTEGRATIVE MEDICINE-JIM, 2025, 23 (01): : 25 - 35
  • [32] Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis
    McDonald, Scott A.
    Pollock, Kevin G.
    Barclay, Stephen T.
    Goldberg, David J.
    Bathgate, Andrew
    Bramley, Peter
    Dillon, John F.
    Fraser, Andrew
    Innes, Hamish A.
    Kennedy, Nicholas
    Morris, Judith
    Went, April
    Hayes, Peter C.
    Hutchinson, Sharon J.
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (03) : 270 - 280
  • [33] Correlation between liver stiffness measurement (LSM) and histology in chronic hepatitis B (CHB) patients receiving oral antiviral treatment: A real-world, single-centre experience
    Yogeswaran, Kumaresan
    Fung, Scott
    HEPATOLOGY, 2012, 56 : 439A - 439A
  • [34] Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
    Lee, Hye Won
    Oh, Se Rim
    Kim, Dong Yun
    Jeong, Yechan
    Kim, Seungtaek
    Kim, Beom Kyung
    Kim, Seung Up
    Kim, Do Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Park, Jun Yong
    GUT AND LIVER, 2018, 12 (03) : 324 - 330
  • [35] Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice
    Tanaka, Takaaki
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Iijima, Hiroko
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    HEPATOLOGY RESEARCH, 2022, 52 (09) : 773 - 783
  • [36] Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
    Alqahtani, Saleh A.
    Yilmaz, Yusuf
    El-Kassas, Mohamed
    Alswat, Khalid
    Sanai, Faisal
    AlZahrani, May
    Abaalkhail, Faisal
    AlShaikh, Manal
    Al-Hamoudi, Waleed K.
    Nader, Fatema
    Stepanova, Maria
    Younossi, Zobair M.
    JOURNAL OF VIRAL HEPATITIS, 2024, 31 (06) : 300 - 308
  • [37] A multi-subgroup predictive model based on clinical parameters and laboratory biomarkers to predict in-hospital outcomes of plasma exchange-centered artificial liver treatment in patients with hepatitis B virus-related acute-on-chronic liver failure
    Liu, Jie
    Shi, Xinrong
    Xu, Hongmin
    Tian, Yaqiong
    Ren, Chaoyi
    Li, Jianbiao
    Shan, Shigang
    Liu, Shuye
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [38] INTERFERON- BASED THERAPIES ARE BENEFICIAL IN CIRRHOTIC HEPATITIS B PATIENTS WITH GOOD LIVER FUNCTION RESERVE: REAL- WORLD EVIDENCE FROM OASIS PROJECT 2.5-YEAR DATA
    Zhang, Qiran
    Sun, Feng
    Yu, Yiqi
    Sui, Shulan
    Zhao, Tingting
    Guo, Ying
    Ren, Wanhua
    Zhang, Jiming
    Huang, Yuxian
    Zhang, Wenhong
    HEPATOLOGY, 2023, 78 : S527 - S528
  • [39] Efficacy and safety of integrative medical program based on blood cooling and detoxification recipe in treating patients with hepatitis B virus related acute-on-chronic liver failure:a randomized controlled clinical study
    刘慧敏
    ChinaMedicalAbstracts(InternalMedicine), 2014, 31 (02) : 72 - 72
  • [40] Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial
    Xu, Wenxiong
    Li, Yangmei
    Wang, Lu
    Gao, Hongbo
    Chen, Jinjun
    Yuan, Jing
    Ouyang, Yi
    Gao, Yufeng
    Li, Jianguo
    Li, Xuejun
    Peng, Liang
    BMJ OPEN, 2021, 11 (12):